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Introduction
Inpatient diabetes management and desirable levelsof glucose control have been an area of controversy over
the past two decades. It has been generally considered a best
practice to target blood glucose levels of 140–180 mg/dL
since publication of the NICE SUGAR Trial.1 Some litera-
ture supports tighter control for specific populations, such as
in the setting of cardiothoracic surgery.2 Many diabetes or-
ganizations have issued guidelines for the intensity of glu-
cose control in the inpatient setting. The American Diabetes
Association (ADA) recommends a general target of 140–
180 mg/dL with flexibility and special considerations for
certain populations.3 This makes delivering diabetes care to
large hospital populations with varied expertise of providers
challenging. Some recent studies have suggested that im-
proved glycemic control may reduce hospital-acquired in-
fections and decrease length of stay, particularly when
implemented in the context of a diabetes management ser-
vice.4 For these reasons, the ADA recommends specialized
inpatient diabetes management services when possible.3
Intensification of the coronavirus disease 2019 (COVID-
19) outbreak caused by the novel coronavirus, severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) has led
to new challenges related to diabetes care in the hospital. The
Center for Disease Control has recognized diabetes as a
significant risk factor for severe COVID-19 disease and
mortality. Patients with COVID-19 and diabetes mellitus
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Introduction: During the coronavirus disease 2019 (COVID-19) outbreak, novel approaches to diabetes care 
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These findings may have implications for reducing nosocomial infection in less challenging times and might 
address shortage of health care providers, especially in the remote areas.
Keywords: COVID-19, Telemedicine, Telehealth, Virtual care, Diabetes mellitus, Inpatient medicine, Hospital 
medicine.
(DM) in the United States from February 12 to March 28,
2020 accounted for 11% of total cases, >24% of hospitali-
zations, and >32% of intensive care unit (ICU) admissions.5
More than 35% of COVID-19 mortality in Italy was associated
with diabetes.6 Patients with DM and COVID-19 appear to
have more difficulty in controlling diabetes.7 Reports suggest
that diabetic ketoacidosis (DKA) is prevalent even in patients
with type 2 diabetes. Severe insulin resistance has been seen,
which requires a different approach to these patients. Some
guidance is now available,7 however more data are needed
to fully understand how to manage these patients effectively.
Clearly, hyperglycemia and ketosis are important risk factors
for health outcomes when COVID-19 is associated with DM.
In addition to difficulty in managing hyperglycemia, dia-
betes care during the COVID-19 pandemic also poses other
challenges. Personal protective equipment (PPE) stewardship
along with efforts to minimize patient and provider exposure
to potential asymptomatic carriers of SARS-CoV-2 poses
challenges for traditional face-to-face care. This led many
inpatient management services to transition to ‘‘virtual care’’
and in some institutions continuous glucose monitoring
(CGM) has been used for inpatient diabetes care by using
telehealth. Even though CGM has not been approved by the
Food and Drug Administration (FDA) for inpatient diabetes
care, the FDA has authorized its use during this COVID-19
pandemic in an attempt to collect new data and facilitate
better diabetes outcomes for the inpatient setting.
On July 1, 2019, the University of North Carolina (UNC)
division of endocrinology launched a diabetes management
service through a diabetes care team (DCT). The goal was to
improve glycemic control and support various services with
automatic consults for hyperglycemia and co-management
through insulin order placement. Before this, the division of
endocrinology had largely worked as a traditional consult
service, making recommendations to primary services with-
out writing orders. Most diabetes consults were reserved for
complicated diabetes care, such as insulin pump manage-
ment. The DCT started with one advanced practice provider
(APP), three rotating attending endocrinologists, and five
rotating endocrine fellows. A second APP was added in
January 2020. Inpatient service teams for which the DCT was
initially deployed were vascular surgery, cardiothoracic
surgery, burn surgery, and the heart failure service.
During the week of March 13, 2020, everything changed
for the DCT. The threat of COVID-19 had increased in North
Carolina and some of the inpatient consult services were
changing to virtual care models to reduce PPE use and de-
crease potential exposures. The division of endocrinol-
ogy followed suit. Initially, we limited physical exams and
shifted inpatient duties to providers younger than 65 years
of age. We also limited potential provider exposures by
rounding away from the patients’ bedside. On March 22,
2020, the service went completely virtual. We aimed at
limiting PPE use as well as limiting patient and provider
exposures, but we also wanted to offer expertise in diabetes
management to all patients infected with COVID-19 and
all patients under investigation (PUI) for COVID-19 with
automatic consults to the diabetes management service. After
multiple weeks of implementation, we reviewed how im-
plementing virtual care has affected glycemic control at
the UNC Medical Center in Chapel Hill, NC. We report our
experience with inpatient diabetes management through
virtual care during the COVID-19 crisis and compare it with
data before the pandemic as well as with data both before and
after transition to virtual care.
Methods
The DCT changed to a virtual care model and stopped all
face-to-face patient contact on March 22, 2020. Patients were
called each morning before 9AM and interviewed by phone
whenever possible. If the patient was not able to be reached
by their phone in their hospital room, a family member was
called. When patients and their families were unable to be
contacted, the primary nurse for the patient was interviewed
each morning. This was performed by two APPs who typi-
cally work Monday through Friday. In addition, attending
endocrinologists and endocrinology fellows occasionally
performed telehealth virtual visits with these patients. Pa-
tients were identified by using an Epic report for the four
participating primary services (vascular surgery, cardiotho-
racic surgery, burn surgery, and medicine heart failure).
A report was run each morning by the APPs that identified
anyone on these four services with a finger stick blood glu-
cose (FSBG) or serum blood glucose test less than 70 mg/dL
or greater than 180 mg/dL. COVID-19 patients and PUIs
were similarly identified for automatic DCT consultation
based on orders for ‘‘COVID-19 contact precautions,’’ a
unique order in our Epic electronic medical record (EMR);
glycemic reports on these patients flagging those with FSBG
or serum glucose <70 or >180 mg/dL, a hemoglobin A1c
(HbA1c) >6.4%, or a diagnosis of diabetes. Automatic con-
sults for these COVID-19 and PUI patients were started on
April 13, 2020. In addition, the DCT APPs have been collec-
ting information on COVID-19 patients, including: HbA1c
before admission, floor versus intensive care unit status, pre-
admission diabetes treatment, and highest total daily dose of
insulin required during admission.
Communication with primary teams while converting to
virtual care was essential. The DCT often communicated
solely through the written note in EMR before the COVID-19
outbreak with primary inpatient providers. However, as a
virtual care telehealth service, we implemented guidelines to
provide verbal and written communication with the primary
team each day. In addition to telephone visits, we utilized
electronic consults for patients unable to communicate with
us. For these consults, we continued to advise the primary
hospital team over the phone. We developed Epic smart
phrases to standardize note templates to enhance clarity of
written communication with the primary teams.
For oversight and collaboration, we continued diabetes
rounds between the APPs, endocrine attending, and the en-
docrine fellow. To limit exposure, we had mandated that
team members work from home when possible. To ensure
adequate communication and to optimize teaching during
rounds, we used Cisco Webex for diabetes rounds. Each
provider took turns sharing the EMR through Webex and
presenting their patients to the team. All team members
could then scrutinize glucose trends from home and provide
collaborative assessments and plans. Five weeks into the
new process, we were able to evaluate our strategy with
FSBG data.
Before the COVID-19 outbreak, we had a data ware-
house created to evaluate FSBG data during our initial
implementation of the DCT. Data are pulled by using Epic
into a data warehouse and include all point-of-care FSBG
tests for the hospital and serum blood glucose levels. These
data include all patients on non-pediatric floors. In addition,
data are linked to individual services, including those that
utilize the DCT.
Data were uploaded from the data warehouse to Microsoft
Excel. Trends were compared both before and after the im-
plementation of the DCT from May 2019 to January 2020.
Data were then compared from January 2020 to April 2020 in
5-week intervals. The first two intervals were the 10 weeks
before implementing virtual care, and the last 5-week interval
was the time in which virtual care was implemented.
Results
Glycemic improvement was achieved for all services by
using the automatic consults after the initial implementation
of the DCT in July 2019. Every service had more blood
glucose readings between 70 and 180 mg/dL that are now
commonly referred to as time-in-range (TIR) after using the
DCT than they had earlier (Fig. 1). Moreover, all services
also increased in the number of blood glucose levels between
70 and 250 mg/dL (Fig. 1). This led to increased health care
system interest in the DCT and the addition of another APP to
the team in January 2020.
We were able to compare the previous glycemic trends
among DCT patients from before to after the transition to
virtual care. The number of point-of-care FSBG tests had
decreased for all services using the DCT from January 2020
to April 2020, likely as a result of a reduction in elective
procedures that were discontinued as COVID-19 admissions
slowly increased. Table 1 shows the number of FSBG tests
from January 12 to April 25, 2020. Figure 2 shows the data
for glycemic levels and highlights the FSBG TIR (70–
180 mg/dL) and an expanded TIR (70–250 mg/dL) in 5-week
intervals before and during virtual care. The proportion
of FSBG results in the two ranges varied from week to
week before and after implementing virtual care but overall
show fair consistency. As an example, for the vascular sur-
gery service, 95% of the FSBG results were between 70 and
250 mg/dL during the week of April 2019 while utilizing
virtual care. Before that, in the preceding 10 weeks, the best
week had been essentially identical. Rates of hypoglycemia
also appeared to be roughly the same both before and after
implementing virtual care (Fig. 2) with overall low rates.
The highest rate was 3.8% on the heart failure service that
occurred before implanting virtual care.
As of April 30, 2020, the DCT provided diabetes
management for the 10 patients with diabetes who were
COVID-19 positive among the 40 patients with COVID-19
precautions (COVID-19 positive or PUI) admitted to our
hospital. Of the 10 patients, 8 were managed without insulin
in the outpatient setting before admission. Despite this, the
average maximal total daily dose of insulin was 73.5 units.
This included a 65-year-old patient treated with metformin
and SGLT2-inhibitor in the outpatient setting with an HbA1c
of 8.2% requiring 261 units of insulin during 24 h in the
ICU. Another 82-year-old patient was treated with sulfo-
nylurea only as an outpatient requiring only 2 units of insulin
FIG. 1. Glycemic TIR (70–180 mg/dL) and time in extended range (181–250 mg/dL) for vascular surgery, cardiothoracic
surgery, medicine heart failure, and burn surgery from May 2019 to April 2020. DCT implemented on July 1, 2019. DCT,
diabetes care team; TIR, time in range.
per day with an HbA1c of 7.2% and he was treated on the
floor. Another ICU patient who was 28 years old required 66
units of insulin in the ICU and had an HbA1c of 13.5%. High
variability in insulin requirements was noted during our
limited experience with these patients during the current
pandemic.
Discussion and Conclusions
We had two goals during the COVID-19 pandemic at
UNC. The first and primary goal was to reduce PPE use and
reduce patient and provider exposure. We accomplished
this by transitioning to a virtual care system. The second
goal was to provide effective diabetes care through virtual
means. Glycemic control has not been affected by transition
to virtual care. This has important implications for future
inpatient diabetes care. Can we provide virtual care to dia-
betes inpatients at other hospitals in our health care system,
several of which do not have diabetes specialty care pro-
viders in their community? Should virtual care become the
standard for inpatients with contact precautions in general?
The bigger question that still remains to be answered is
whether reimbursement by the insurers will continue in future
(post COVID-19) to be similar to the current COVID-19
pandemic period.
In addition to transitioning how we delivered care, we
wanted to make ourselves available to inpatients affected by
COVID-19, both to ensure optimal diabetes care in the hos-
pital and, more importantly, to facilitate speedy transitions of
care from the ICU to the floor and from the floor to the
outpatient setting. Our APPs provide ongoing diabetes care
to COVID-19 patients after discharge until they are able to
establish care with their usual outpatient providers. For-
tunately, UNC had fewer cases than predicted in April
2020, and we were able to plan our diabetes care thought-
fully. Though our experience with COVID-19 has been
limited, hospitalizations in our state are still increasing. Au-
tomatic consults to patients with COVID-19 and PUI have









January 12–February 15, 2020 917 1570 943 1482
February 16–March 21, 2020 907 2226 588 1605
March 22–April 25, 2020 542 1381 400 835
FSBG, finger stick blood glucose.
FIG. 2. Glycemic levels for teams utilizing the DCT during the transition from face-to-face care to virtual care. Virtual
care implemented on March 22, 2020. TIR (70–180 mg/dL) and expanded TIR (181–250 mg/dL) highlighted earlier with no
significant change noted from before and after implementation of virtual care.
allowed the primary hospitalist and ICU teams caring for
these patients to focus on the multimorbidity that these pa-
tients experience, and transitions of care have not been held
up for glycemic control issues.
Variability in insulin requirements among patients with
COVID-19 has been remarkable. We recently received au-
thorization from the hospital administration to use CGM for
diabetes management and believe that this will reduce PPE
requirements even further and provider and patient expo-
sures as well as further facilitate glycemic control by using
cloud-based telehealth. There have been recent reports of
using telehealth successfully in new-onset patients with
type 1 diabetes and keeping patients away from the hospital
admissions even in the presence of DKA.8,9
The trajectory of the COVID-19 pandemic seems to be
slow and prolonged in North Carolina, with most new cases
coming from congregate living and workplace clusters. This
suggests that the need to preserve PPE will extend for many
months. Virtual care will need to continue. We have shown
(through limited data) that we can effectively provide care by
using a virtual model. Rates of hyperglycemia and hypo-
glycemia did not significantly differ after transitioning to
virtual care. There are obvious limitations to our data, given
the short time since the transition to virtual care occurred.
The sample size is small and we did not use CGM in our
model even though it was authorized recently by the FDA for
inpatient settings during COVID-19. Applying these learn-
ings may benefit inpatients with hyperglycemia in dispersed
communities, especially in remote places where specialized
diabetes care may not be available. Telehealth also may have
the potential to reduce the risk of nosocomial infections in
the future.
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